Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02794181 · ClinicalTrials.gov registry record

Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
34
Enrollment target

NCT02794181: Completed study, sponsored by National Institutes of Health Clinical Center (CC).

NCT02794181 is a clinical trial that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02794181 has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
34 participants
Enrollment target

Study Summary

Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby. The virus can also spread by blood transfusion and sexual intercourse. This is why the U.S. Food \& Drug Administration (FDA) recommended that people should not give blood if possibly exposed to Zika virus. Dengue virus and chikungunya virus are passed by the same mosquitoes as Zika virus. These can cause severe reactions if passed through transfused blood. Donated blood is usually not tested for these three viruses. Researchers want to count the infections in people who have been exposed because of travel or sexual exposure. They want to learn the risk these viruses might pose to the U.S. blood supply. They also want to study the natural history of these viruses by following infected people over time. Objective: To study the risk of Zika, dengue, and chikungunya viruses to the U.S. blood supply. Eligibility: Adults age 18 or older who were turned down for donating blood because of possible exposure to certain viruses. Design: Participants will have blood and urine tests. They will answer questions about their travel. They will be called in about a week with virus test results. Participants with negative results do not have any more study visits. Participants with positive results will be asked to stay in the study for 6 months. They will have weekly clinic visits and tests until results are negative for 2 straight weeks. Once test results are negative, they will have monthly visits. Visits will include physical exams, blood and urine samples, and optional semen samples from men. Most people will have 3-4 weekly visits and 5 monthly visits.

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2016-06-08
Est. Completion 2019-03-14

What the finished NCT02794181 record still lists

NCT02794181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT02794181 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02794181 about?

NCT02794181 is a clinical study titled "Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)". Background: Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby. The virus can also spread by blood transfusion and sexual intercourse. This is why the U.S. Food \& Drug Administrati...

What is the current status of trial NCT02794181?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2016-06-08. Estimated completion is 2019-03-14.

Who is sponsoring clinical trial NCT02794181?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02794181, the US trial registry maintained by the National Library of Medicine. NCT02794181 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.